Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To explore the lower urinary tract symptoms (LUTS), especially those in the urinary storage phase, following transurethral resection of the prostate (TURP), and to improve the postoperative management and patients' quality of life after TURP.
Methods: A total of 86 patients with benign prostate hyperplasia (BPH) underwent TURP, and were interviewed on urinary symptoms at 1, 3, 7, 15 and 30 days after removal of the catheter. The patients were divided into two groups according to whether they had preoperative detrusor instability and/or compliance of the bladder (Group A) or not (Group B), and observed for the changes in IPSS scores and urinary storage symptoms after removal of the catheter.
Results: Complete follow-ups were achieved in 71 cases, 28 with detrusor instability and/or compliance of the bladder and the other 43 without. Their IPSS scores on the 1st, 3rd, 7th, 15th and 30th day after removal of the catheter were 8.1 +/- 2.5, 7.2 +/- 3.1, 6.3 +/- 3.8, 5.3 +/- 4.2 and 2.4 +/- 3.4, respectively, with statistically significant differences between the 7th and the 1st as well as the 30th and the 15th day (P < 0.05), but not between the 1st and the3rd nor the 15th and the 7th day (P > 0.05). On the 1st day, the cardinal symptoms in the urinary storage phase were urinary frequency, urgency and incontinence; the scores on IPSS and urinary storage symptoms were 10.4 +/- 3.3 and 9.3 +/- 3.8 in Group A and 6.2 +/- 2.8 and 5.2 +/- 2.7 in Group B, with significant differences between the two groups (P < 0.05). After treatment with tolterodine and alpha-adrenoreceptor inhibitor, neither IPSS scores nor the scores on urinary storage symptoms showed any significant differences between Groups A and B on the 15th and 30th day (P > 0.05).
Conclusion: The lower urinary tract symptoms following TURP, especially those in the urinary storage phase, are correlated with preoperative bladder function, and getting improved gradually after surgery.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Detection of Anabolic Androgenic Steroids and Steroid Esters-Comparing Dried Blood Spots Collection Devices and Urine Samples.
Drug Test Anal
September 2025
Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Dried blood spots (DBS) have emerged as a promising complement, and in some settings, an alternative, to urine for anabolic androgenic steroid (AAS) testing, offering advantages such as minimal invasiveness, simplified storage, and transportation. This study evaluated two DBS collection devices-cellulose-based Capitainer-B50 and polymer-based Tasso-M20-and compared results with traditional urine analysis. Ten self-reported AAS users were recruited and provided matched urine and DBS samples.
View Article and Find Full Text PDFPolypyrrole functionalized (TiCT -SnO NPs) nanocomposite-based hybrid capacitive electrode for electrochemical detection of .
RSC Adv
September 2025
Department of Chemical Engineering, Jashore University of Science and Technology Jashore 7408 Bangladesh
Bacterial detection is crucial for accurate clinical diagnostics and effective environmental monitoring. Particularly, , a pathogenic bacterium, can cause a wide range of infections, including meningitis, bloodstream infections, pneumonia, urinary tract infections, and wound or surgical site infections. Herein, a polypyrrole (PPy) functionalized TiCT -tin dioxide nanoparticle (SnO NPs) nanocomposite-based hybrid capacitive electrode for the electrochemical detection of ATCC 700603 is developed.
View Article and Find Full Text PDFMarked Improvements in Airway Abnormalities and Multifaceted Outcomes After 2 Years Switching to Avalglucosidase Alfa: Evaluation of A 19-Year-Old Male Diagnosed With Late-Onset Pompe Disease.
Am J Med Genet A
September 2025
Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan.
Pompe disease (PD), a severe inherited metabolic myopathy caused by the deficiency of acid α-glucosidase (GAA), is characterized by progressive myopathy with reduced muscle strength, endurance, and respiratory insufficiency. The primary GAA deficiency treatment is enzyme replacement therapy (ERT) with alglucosidase alfa; however, its long-term efficacy seems to diminish with time. In 2021, a new ERT medication, avalglucosidase alfa, was approved for patients over 6 months of age with PD in Taiwan.
View Article and Find Full Text PDFClinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.
Urology
September 2025
Sumitomo Pharma America, Inc., Marlborough, MA.
Objective: To demonstrate the impact of vibegron treatment in the phase 3 COURAGE trial (NCT03902080) on clinically meaningful response parameters in men with overactive bladder (OAB) receiving pharmacological therapy for benign prostatic hyperplasia (BPH) as measured by standard, validated patient-reported outcomes.
Methods: Men >45 years with OAB receiving pharmacotherapy for BPH were randomly assigned 1:1 to vibegron 75 mg or placebo for 24 weeks. Participants completed bladder diaries assessing changes in micturition frequency, nocturia, and urge urinary incontinence (UUI); International Prostate Symptom Score (IPSS); and OAB questionnaire (OAB-q).
Efficacy, feasibility, and safety of aquablation after previous urolift treatment of lower urinary tract symptoms secondary to benign prostate hyperplasia: a retrospective cohort study.
World J Urol
September 2025
Urology Department - Frimley Park Hospital NHS Foundation Trust, Portsmouth Road, Frimley, Camberley, GU16 7UJ, England.
Purpose: The influence of a previous Urolift treatment on the outcomes of prostate Aquablation is still controversial. This retrospective cohort study aimed to evaluate the perioperative outcomes, efficacy, feasibility, and safety of Aquablation after previous Urolift treatment.
Methods: The charts of patients with benign prostate hyperplasia (BPH) complicated by storage and voiding symptoms, who were previously treated with Urolift followed by Aquablation between January 2022 and July 2024, were retrospectively reviewed and analyzed for changes in International Prostate Symptom Score (IPSS), maximum urinary flow rates (Qmax), and postvoid residual volume (PVR) from baseline (pre-Aquablation) to the mean of three months postoperatively.